A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)
PHASE2CompletedINTERVENTIONAL
Enrollment
150
Participants
Timeline
Start Date
September 30, 2002
Study Completion Date
April 30, 2003
Conditions
-Unhealthy Children With a History of Prematurity
Interventions
DRUG
MEDI-493
Active Comparator
Trial Locations (1)
94304
Packard Children's Hospital at Stanford, Palo Alto